BioLine RX SG&A Expenses

Selling, General & Administrative Expenses of BioLine RX is 29.59 M USD in 2026.

Selling, General & Administrative Expenses of BioLine RX changed from 31.23 M USD to 29.59 M USD, representing a -5.26% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Selling, General & Administrative Expenses BioLine RX since 2006 – with annual values, charts, and detailed analysis.

SG&A expenses include all non-production costs such as salaries, marketing, rent, and administrative overhead. They are a key component of operating expenses.

Selling, General & Administrative Expenses's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Selling, General & Administrative Expenses's BioLine RX historically and in real time.